• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-04

  Anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor with nanomolar efficacy against VEGFR2, PDGFRβ, and FGFR1. It demonstrates superior anti-angiogenic and anti-proliferative activity in preclinical and clinical cancer research, with favorable safety and pharmacokinetic profiles. APExBIO supplies reference-grade anlotinib hydrochloride for research applications.

• PBS (Phosphate-Buffered Saline): Technical Use and Protocols

  2026-06-04

  PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer that supports consistent cell washing, substance dilution, and routine in vitro laboratory workflows requiring physiological pH and osmolarity. This buffer should not be used for diagnostic or medical purposes and is strictly for scientific research applications.

• PLK1-Mediated Phosphorylation of p31comet Regulates Mitotic

  2026-06-03

  This study clarifies how Polo-like kinase 1 (PLK1) regulates the action of p31comet in the disassembly of mitotic checkpoint complexes, revealing a phosphorylation-dependent suppression mechanism. These findings illuminate a critical control point for mitotic progression, with direct implications for the design and application of PLK1 inhibitors in cell cycle and cancer research.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo

  2026-06-03

  This study characterizes anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, with primary action against VEGFR2-mediated angiogenesis crucial for tumor growth. The findings highlight its superior specificity, robust anti-angiogenic activity, and favorable pharmacological profile, providing a valuable tool for cancer research and translational anti-angiogenic strategies.

• Acetylcysteine in Tumor-Stroma Redox Modeling: Next-Gen Insi

  2026-06-02

  Explore how acetylcysteine advances patient-specific tumor-stroma redox modeling and chemoresistance research. This in-depth analysis reveals new mechanistic insights and practical protocols for using acetylcysteine in 3D co-culture systems.

• Polymyxin B Sulfate: Optimized Workflows for MDR Infection R

  2026-06-02

  Polymyxin B sulfate, supplied by APExBIO, empowers researchers to address multidrug-resistant Gram-negative infections with precision. This article details advanced experimental workflows, troubleshooting strategies, and directly actionable protocol parameters to accelerate both infection modeling and immunological assays.

• Pazopanib Hydrochloride: Advanced Experimental Workflow in C

  2026-06-01

  Pazopanib Hydrochloride (GW786034) empowers researchers with multi-target kinase inhibition for precise anti-angiogenic and tumor suppression studies. This article delivers actionable workflows, troubleshooting guidance, and practical assay enhancements, bridging recent in vitro methodology advances to maximize reproducibility and translational impact.

• Optimized hiPSC Platelet Differentiation via Small Molecule

  2026-06-01

  This study presents an optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), leveraging increased embryoid body input, serum-free media, and targeted small molecule supplementation. The approach significantly increases platelet yield, reduces production time and cost, and demonstrates the importance of kinase pathway modulation—including c-Met inhibition—for efficient megakaryocyte maturation.

• Neddylation Inhibition, SPOP-ASCT2 Axis, and Glutamine Metab

  2026-05-31

  The reference study uncovers how inhibiting neddylation boosts glutamine uptake in breast cancer cells by disrupting CRL3SPOP E3 ligase-mediated degradation of the transporter ASCT2. This mechanistic insight reveals the SPOP-ASCT2 axis as a key regulatory node for metabolic adaptation in tumors and suggests new combination strategies for targeted cancer therapy.

• Cabozantinib (XL184) in RCC: Protocols, Adaptation, and Assa

  2026-05-30

  Leverage Cabozantinib (XL184) as a multi-kinase inhibitor to model both acute and chronic adaptation in renal cell carcinoma research. This article translates phosphoproteomic insights into actionable workflows, troubleshooting strategies, and advanced applications for robust antiangiogenic and motility studies.

• Phosphoproteomic Remodeling in RCC under Chronic Cabozantini

  2026-05-29

  This study reveals how renal cell carcinoma (RCC) cells adaptively remodel their phosphoproteome in response to acute versus chronic Cabozantinib (XL184) treatment. By mapping timescale-dependent signaling changes, the research uncovers pathway-specific adaptations and motility shifts, offering a systems-level framework for kinase inhibitor research.

• X-Gal in Blue-White Colony Screening: Protocols & Advances

  2026-05-29

  X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) remains the gold standard for blue-white colony screening, offering unmatched clarity and reliability in recombinant DNA workflows. This article delivers actionable protocols, troubleshooting strategies, and the latest research-backed enhancements for maximizing assay precision with APExBIO’s high-purity X-Gal.

• AZD3463 ALK/IGF1R Inhibitor: Advanced Workflows for Neurobla

  2026-05-28

  AZD3463 sets a new benchmark for ALK/IGF1R inhibition in neuroblastoma research, offering precise modulation of the PI3K/AKT/mTOR axis and robust synergy with standard chemotherapeutics. This article translates reference-backed innovations and real-world troubleshooting into actionable protocols, empowering researchers to overcome resistance and maximize experimental reproducibility.

• Pomalidomide (CC-4047): Protocol Optimization for Myeloma Re

  2026-05-28

  Pomalidomide (CC-4047) is redefining experimental workflows in hematological malignancy research by offering targeted tumor microenvironment modulation and robust cytokine inhibition. This guide delivers step-by-step protocols, troubleshooting strategies, and actionable insights grounded in recent mutational landscape studies, uniquely positioning researchers to tackle multiple myeloma heterogeneity and drug resistance.

• Antipyrine in CNS Drug Discovery: Applied Workflows & BBB As

  2026-05-27

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) stands out as a validated reference for high-throughput blood-brain barrier (BBB) and pharmacokinetic studies, streamlining CNS drug discovery. This guide delivers actionable protocols, data-driven troubleshooting, and insights from the latest surrogate BBB model innovations.

14731 records 1/983 page Next 12345 下5页 Last page